Literature DB >> 19522825

Multiple endocrine neoplasia type 1: a chromatin writer's block.

K M A Dreijerink1, C J M Lips, H Th M Timmers.   

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is caused by inactivating germ line mutations of the MEN1 tumour suppressor gene. The MEN1 gene product, menin, participates in many cellular processes, including regulation of gene transcription. As part of a protein complex that writes a trimethyl mark on lysine 4 of histone H3 (H3K4me3), menin is involved in activating gene transcription. Several functions of the menin histone methyltransferase complex have been discovered through protein interaction studies. Menin can interact with nuclear receptors and regulate transcription of hormone responsive target genes. Menin regulates transcription of cyclin-dependent kinase inhibitor and Hox genes via the chromatin-associated factor LEDGF. Aberrant expression of menin target genes in tumours in MEN1 patients suggests that loss of writing of the H3K4me3 mark contributes to MEN1 tumourigenesis. At present, drugs are being developed that target chromatin modifications. The identification of compounds that could restore H3K4me3 on menin target genes would provide new therapeutic strategies for MEN1 patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19522825     DOI: 10.1111/j.1365-2796.2009.02115.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  9 in total

1.  Altered MENIN expression disrupts the MAFA differentiation pathway in insulinoma.

Authors:  Z Hamze; C Vercherat; A Bernigaud-Lacheretz; W Bazzi; R Bonnavion; J Lu; A Calender; C Pouponnot; P Bertolino; C Roche; R Stein; J Y Scoazec; C X Zhang; M Cordier-Bussat
Journal:  Endocr Relat Cancer       Date:  2013-10-24       Impact factor: 5.678

Review 2.  The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes.

Authors:  Edwin Smith; Ali Shilatifard
Journal:  Mol Cell       Date:  2010-12-10       Impact factor: 17.970

Review 3.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

4.  MEN1 is a melanoma tumor suppressor that preserves genomic integrity by stimulating transcription of genes that promote homologous recombination-directed DNA repair.

Authors:  Minggang Fang; Fen Xia; Meera Mahalingam; Ching-Man Virbasius; Narendra Wajapeyee; Michael R Green
Journal:  Mol Cell Biol       Date:  2013-05-06       Impact factor: 4.272

5.  Multiple endocrine neoplasias: advances and challenges for the future.

Authors:  M Alevizaki; C A Stratakis
Journal:  J Intern Med       Date:  2009-07       Impact factor: 8.989

6.  The menin tumor suppressor protein is phosphorylated in response to DNA damage.

Authors:  Joshua Francis; Wenchu Lin; Orit Rozenblatt-Rosen; Matthew Meyerson
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

7.  Knockdown of menin affects pre-mRNA processing and promoter fidelity at the interferon-gamma inducible IRF1 gene.

Authors:  Lauren B Auriemma; Shaili Shah; Lara M Linden; Melissa A Henriksen
Journal:  Epigenetics Chromatin       Date:  2012-01-12       Impact factor: 4.954

Review 8.  Multifaceted Targeting of the Chromatin Mediates Gonadotropin-Releasing Hormone Effects on Gene Expression in the Gonadotrope.

Authors:  Philippa Melamed; Majd Haj; Yahav Yosefzon; Sergei Rudnizky; Andrea Wijeweera; Lilach Pnueli; Ariel Kaplan
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-27       Impact factor: 5.555

Review 9.  Biochemical, bone and renal patterns in hyperparathyroidism associated with multiple endocrine neoplasia type 1.

Authors:  Delmar M Lourenço; Flavia L Coutinho; Rodrigo A Toledo; Tatiana Denck Gonçalves; Fabio L M Montenegro; Sergio P A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.